PL2598525T3 - Mutanty frataksyny - Google Patents

Mutanty frataksyny

Info

Publication number
PL2598525T3
PL2598525T3 PL11788225T PL11788225T PL2598525T3 PL 2598525 T3 PL2598525 T3 PL 2598525T3 PL 11788225 T PL11788225 T PL 11788225T PL 11788225 T PL11788225 T PL 11788225T PL 2598525 T3 PL2598525 T3 PL 2598525T3
Authority
PL
Poland
Prior art keywords
frataxin
mutants
frataxin mutants
Prior art date
Application number
PL11788225T
Other languages
English (en)
Inventor
Roberto Testi
Original Assignee
Roberto Testi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roberto Testi filed Critical Roberto Testi
Publication of PL2598525T3 publication Critical patent/PL2598525T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0091Oxidoreductases (1.) oxidizing metal ions (1.16)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y116/00Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/03Oxidoreductases oxidizing metal ions (1.16) with oxygen as acceptor (1.16.3)
    • C12Y116/03001Ferroxidase (1.16.3.1), i.e. ceruloplasmin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11788225T 2010-07-28 2011-07-27 Mutanty frataksyny PL2598525T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36857610P 2010-07-28 2010-07-28
EP11788225.8A EP2598525B1 (en) 2010-07-28 2011-07-27 Frataxin mutants
PCT/IB2011/002511 WO2012014083A2 (en) 2010-07-28 2011-07-27 Frataxin mutants

Publications (1)

Publication Number Publication Date
PL2598525T3 true PL2598525T3 (pl) 2016-03-31

Family

ID=45044630

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11788225T PL2598525T3 (pl) 2010-07-28 2011-07-27 Mutanty frataksyny

Country Status (12)

Country Link
US (2) US9217019B2 (pl)
EP (2) EP3012267A1 (pl)
CA (1) CA2806303C (pl)
DK (1) DK2598525T3 (pl)
ES (1) ES2552456T3 (pl)
HR (1) HRP20151238T1 (pl)
HU (1) HUE028111T2 (pl)
PL (1) PL2598525T3 (pl)
PT (1) PT2598525E (pl)
SI (1) SI2598525T1 (pl)
SM (1) SMT201500264B (pl)
WO (1) WO2012014083A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
WO2016103223A1 (en) * 2014-12-23 2016-06-30 Fratagene Therapeutics Ltd. Methods of treating friedreich's ataxia using src inhibitors
MX2017009336A (es) * 2015-01-16 2017-11-15 Voyager Therapeutics Inc Polinucleótidos dirigidos al sistema nervioso central.
US10517877B2 (en) 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression
WO2018089527A1 (en) * 2016-11-09 2018-05-17 Intrexon Corporation Frataxin expression constructs
US11759533B2 (en) 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
EP3999102A1 (en) 2019-07-18 2022-05-25 Larimar Therapeutics, Inc. Use of frataxin for treating leigh syndrome, french canadian type
BR112022001657A2 (pt) 2019-07-29 2022-03-22 Univ Indiana Trustees Polipeptídeo de fusão, sequência de ácidos nucleicos, cassete de expressão, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para tratar a ataxia de friedreich e para tratar uma doença associada à ataxia de friedreich
WO2021021964A2 (en) 2019-07-29 2021-02-04 Chondrial Therapeutics, Inc. Methods of quantifying frataxin and frataxin fusion proteins
KR20220108094A (ko) 2019-11-25 2022-08-02 라리마 테라퓨틱스, 인코포레이티드 프라탁신 활성의 정량화 방법
US11976100B2 (en) 2020-04-30 2024-05-07 Larimar Therapeutics, Inc. Methods for treating myelin associated diseases and mitochondria associated diseases
CN116867506A (zh) 2020-12-12 2023-10-10 拉利玛生物医药公司 包括弗里德赖希共济失调蛋白融合蛋白的药物组合物及其使用方法
WO2026077951A1 (en) 2024-10-07 2026-04-16 Vico Therapeutics B.V. Improved aon for rna editing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AT500929B1 (de) * 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2011070444A2 (en) * 2009-12-07 2011-06-16 Roberto Testi Compositions and methods for treating friedreich's ataxia

Also Published As

Publication number Publication date
HRP20151238T1 (hr) 2015-12-18
EP3012267A1 (en) 2016-04-27
US20130196932A1 (en) 2013-08-01
CA2806303C (en) 2018-01-02
US9217019B2 (en) 2015-12-22
ES2552456T3 (es) 2015-11-30
WO2012014083A2 (en) 2012-02-02
DK2598525T3 (da) 2015-09-21
PT2598525E (pt) 2015-11-02
WO2012014083A3 (en) 2012-04-19
CA2806303A1 (en) 2012-02-02
EP2598525B1 (en) 2015-08-19
US9944906B2 (en) 2018-04-17
HUE028111T2 (en) 2016-11-28
SI2598525T1 (sl) 2016-02-29
US20160060605A1 (en) 2016-03-03
EP2598525A2 (en) 2013-06-05
SMT201500264B (it) 2016-01-08

Similar Documents

Publication Publication Date Title
HRP20181800T1 (hr) Bunar
AP3607A (en) Substituted imidazopyridazines
SI2598525T1 (sl) Mutanti frataksina
AP3107A (en) 5-Alkynyl-pyrimidines
SMT201700319T1 (it) Pirrolidin-2-carbossammidi sostituite
GB201012176D0 (en) Well
GB201008340D0 (en) Biomarkers
GB201021502D0 (en) Biomarkers
GB201018056D0 (en) Biomarkers
IL230217B (en) New mutations ecd–r17–il
ZA201304430B (en) Substituted sodium-1h-pyrazole-5-olate
GB201004442D0 (en) Biomarker
GB201005561D0 (en) Biomarkers
GB201001444D0 (en) Biomarkers
GB201010316D0 (en) Biomarkers
GB201103569D0 (en) Mutants
GB201005456D0 (en) Biomarkers
GB201015267D0 (en) An object forming assembly
EP2588088A4 (en) SOLID SHAPES
GB201001419D0 (en) Biomarkers
GB2487707B (en) Sliding gauge
GB201008727D0 (en) Biomarkers
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4536P (en) TB01 Tibouchina urvilleana
GB201005563D0 (en) Biomarkers